Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 6Peritoneal Neoplasms 2Colorectal Neoplasms 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Solid Neoplasm 1Sarcoma 1Rectal Neoplasms 1Pleural Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mediastinal Neoplasms 1HIV Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Anal Canal Carcinoma 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 234Leucovorin 209Irinotecan 152Radiotherapy 138Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 48Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Mitozytrex × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡